HLA
ACHN

Hamilton Lane Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Hamilton Lane Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-29,846
Closed -$264K – 64
2015
Q2 		$264K Buy
+29,846
New +$282K 0.1% 56
2014
Q4 		– Sell
-22,202
Closed -$222K – 71
2014
Q3 		$222K Buy
+22,202
New +$206K 0.07% 50

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hamilton Lane Advisors's ACHN Position: Q3 2015 in Review

Hamilton Lane Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2015, closing a stake of 29,846 shares — an estimated $264K sold.

Hamilton Lane Advisors first reported a position in ACHN in Q3 2014 and held it in 2 quarters. The position peaked at $264K in Q2 2015. 141 funds tracked by Wall St. Rank hold ACHN as of Q3 2015.

  • Hamilton Lane Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 29,846 Achillion Pharmaceuticals shares in Q3 2015, an estimated $264K.
  • Hamilton Lane Advisors first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Hamilton Lane Advisors's Achillion Pharmaceuticals position peaked at $264K in Q2 2015.
  • 141 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2015.

Based on Hamilton Lane Advisors's 13F filing for Q3 2015, filed 19 Oct 2015.